NEws
TEAM
New hires strengthen R&D and data science teams
We’re excited to share that Arpelos has raised $12 million in seed funding to fuel the next stage of our growth. The round was led by top-tier biotech investors who share our belief in the need for better tools to understand therapeutic complexity at the cellular level. With this support, we’ll expand our team, scale our operations, and bring our platform to more pharma and biotech partners around the world.
A platform built to reveal what others miss
Modern drug discovery is constrained by tools that oversimplify biology. Arpelos was founded to change that. Our platform uses fresh human blood and high-dimensional single-cell profiling to capture how compounds behave across real, diverse cell populations—before a molecule ever enters the clinic.
This funding allows us to advance our core technology: increasing throughput, expanding our functional readouts, and improving the resolution of our cellular insights. With more data, better models, and smarter tools, we aim to bring unprecedented clarity to drug behavior in human biology.
Expanding the team and scaling with purpose
This funding isn't just about growth—it's about collaboration. We’re already working with leading pharma teams on pilot programs that explore compound behavior, mechanism of action, and pleiotropic effects in human blood. These early partnerships are proving that a more detailed, human-first approach to preclinical research can yield more confident decisions downstream.
What’s next
We're also investing in infrastructure to make our platform more scalable and accessible to partners. From automation to improved data pipelines, these operational upgrades will help us serve more programs, faster—while maintaining the scientific depth we’re known for. We’re refining every layer of the workflow, from sample handling and compound processing to data analysis and reporting, so partners can get high-resolution insights with speed and consistency.
As demand grows, we’re building toward a future where large-scale, parallelized compound profiling becomes routine—not rare. Our goal is to make blood-based functional readouts a standard part of the preclinical toolkit, helping teams make smarter decisions with real-world biology as the foundation
“We’re building the kind of infrastructure that lets you ask complex questions—and actually get answers fast, without compromising scientific depth.”
Dr. Lina Kovach
Arpelos Founder
Turning data into decisions—faster
We’re not just generating high-resolution data—we’re making it actionable. Our platform is designed to surface clear insights that inform decision-making in real time, not months later. By integrating transcriptomic, functional, and phenotypic data into unified profiles, we help partners understand how a drug behaves across the full spectrum of human blood cell types.
These insights enable teams to move with more confidence: identifying early liabilities, comparing candidate molecules, or discovering unexpected mechanisms of action. As we scale, we’re focused on reducing turnaround time even further—so the science moves as quickly as the strategy.
Image Credit Arpelos Labs
fig.01
Image Credit Arpelos Labs
fig.02
Building strong partnerships with pharma and biotech
This funding isn't just about growth—it's about collaboration. We’re already working with leading pharma teams on pilot programs that explore compound behavior, mechanism of action, and pleiotropic effects in human blood. These early partnerships are proving that a more detailed, human-first approach to preclinical research can yield more confident decisions downstream.
As we expand, we’re focused on building relationships with teams who value translational relevance and want to ask better questions, earlier. If you're interested in partnering, we’d love to hear from you.
Arpelos News
Latest updates from the lab, the team, and beyond.
Go to news page
STAY IN THE LOOP
Stay in the loop
as we build
what's next
Get occasional updates on our research, progress, and partnerships — no noise, just meaningful news from the Arpelos team.
Your email adress…
